Staff Members - Benha University
Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease
• 2021
Publication Information
Authors
Mona M. Allama , Reham M. Ibrahima
, Walaa Bayoumie El Gazzarb,c and Mona A. Said
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Context: Inflammatory and immune pathways play a crucial role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD). Sitagliptin blocks the dipeptidyl peptidase-4 (DPP-4) enzyme, mechanisms that alter inflammatory pathways and the innate immune system, and by which Sitagliptin
affects the pathogenesis of NAFLD weren’t previously discussed.
Objective: This study aims to understand the interaction between Sitagliptin and innate immune
response in order to meliorate NAFLD.
Methods: Thirty- two Wistar male albino rats were categorised into four groups. Rats have received a
standard diet or a high-fat diet either with or without Sitagliptin. Serum HMGB1, protein and mRNA
expressions of hepatic TLR4 and NF-jB, inflammatory cytokines, and histopathological changes
were analysed.
Results: An ameliorative action of Sitagliptin in NAFLD was demonstrated via decreasing HMGB1-
mediated TLR4/NF-jB signalling in order to suppress inflammation and reduce insulin resistance.
Conclusion: Sitagliptin may in fact prove to be a beneficial therapeutic intervention in NAFLD.
affects the pathogenesis of NAFLD weren’t previously discussed.
Objective: This study aims to understand the interaction between Sitagliptin and innate immune
response in order to meliorate NAFLD.
Methods: Thirty- two Wistar male albino rats were categorised into four groups. Rats have received a
standard diet or a high-fat diet either with or without Sitagliptin. Serum HMGB1, protein and mRNA
expressions of hepatic TLR4 and NF-jB, inflammatory cytokines, and histopathological changes
were analysed.
Results: An ameliorative action of Sitagliptin in NAFLD was demonstrated via decreasing HMGB1-
mediated TLR4/NF-jB signalling in order to suppress inflammation and reduce insulin resistance.
Conclusion: Sitagliptin may in fact prove to be a beneficial therapeutic intervention in NAFLD.